Epitope of IP-10 and antibody to same

Patent metadata

Field	Value
Publication number	US-9725507-B2
Application number	US-201314428301-A
Country	US
Kind code	B2
Filing date	Sep 17, 2013
Priority date	Sep 17, 2012
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The present invention relates to a novel epitope of IP-10 (IFN-γ-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to IP-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to IP-10. The anti-IP-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to IP-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

First claim

What is claimed is:

1. An antibody or antigen-binding fragment thereof which specifically binds to an epitope of SEQ ID NO:5 wherein the antibody or the antigen-binding fragment comprises a heavy chain variable region and light chain variable region including the following CDR (Complementarity Determining Region) H1, H2 and H3 and CDR L1, L2 and L3:
(i) CDR H1 of SEQ ID NO: 51, CDR H2 of SEQ ID NO: 52 and CDR H3 of SEQ ID NO: 53, and CDR L1 of SEQ ID NO: 72, CDR L2 of SEQ ID NO: 73 and CDR L3 of SEQ ID NO: 74;
(ii) CDR H1 of SEQ ID NO: 54, CDR H2 of SEQ ID NO: 55 and CDR H3 of SEQ ID NO: 56, and CDR L1 of SEQ ID NO: 75, CDR L2 of SEQ ID NO: 76 and CDR L3 of SEQ ID NO: 77;
(iii) CDR H1 of SEQ ID NO: 57, CDR H2 of SEQ ID NO: 58 and CDR H3 of SEQ ID NO: 59, and CDR L1 of SEQ ID NO: 78, CDR L2 of SEQ ID NO: 79 and CDR L3 of SEQ ID NO: 80;
(iv) CDR H1 of SEQ ID NO: 60, CDR H2 of SEQ ID NO: 61 and CDR H3 of SEQ ID NO: 62, and CDR L1 of SEQ ID NO: 81, CDR L2 of SEQ ID NO: 82 and CDR L3 of SEQ ID NO: 83;
(v) CDR H1 of SEQ ID NO: 63, CDR H2 of SEQ ID NO: 64 and CDR H3 of SEQ ID NO: 65, and CDR L1 of SEQ ID NO: 84, CDR L2 of SEQ ID NO: 85 and CDR L3 of SEQ ID NO: 86;
(vi) CDR H1 of SEQ ID NO: 66, CDR H2 of SEQ ID NO: 67 and CDR H3 of SEQ ID NO: 68, and CDR L1 of SEQ ID NO: 87, CDR L2 of SEQ ID NO: 88 and CDR L3 of SEQ ID NO: 89; or
(vii) CDR H1 of SEQ ID NO: 69, CDR H2 of SEQ ID NO: 70 and CDR H3 of SEQ ID NO: 71, and CDR L1 of SEQ ID NO: 90, CDR L2 of SEQ ID NO: 91 and CDR L3 of SEQ ID NO: 92.

2. The antibody or an antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment comprises a heavy chain and a light chain, and the heavy chain and the light chain consist of the amino acid sequence set forth in SEQ ID NOs: (i) 93 and 94, (ii) 95 and 96, (iii) 97 and 98, (iv) 99 and 100, (v) 101 and 102, (vi) 103 and 104, or (vii) 105 and 106.

3. A nucleic acid molecule encoding the heavy chain variable and light chain variable region of the antibody or antigen-biding fragment thereof according to claim 1 .

4. A nucleic acid molecule encoding the heavy chain and light chain of the antibody or antigen-biding fragment thereof according to claim 2 .

5. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to claim 2 and a pharmaceutically acceptable carrier.

Assignees

• Snu R&Db Foundation

Inventors

• Song Yeong Wook

Classifications

• C07K14/522

  Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/24 Primary

  against cytokines, lymphokines or interferons · CPC title